Tribe Public Hosts CEO Webinar on Future of Life Sciences

Serina Therapeutics' CEO to present on navigating the new FDA era and strategic priorities for 2026

Feb. 3, 2026 at 6:15am

Got story updates? Submit your updates here. ›

Serina Therapeutics, a clinical-stage biotechnology company, has announced that its CEO, Steven Ledger, will present at a Tribe Public webinar event titled "Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences". The event is scheduled for Wednesday, February 4, 2026 and will cover how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sector.

Why it matters

This webinar provides valuable insights into the evolving regulatory landscape and strategic priorities for life sciences companies as they navigate the "new FDA era" in 2026. Serina Therapeutics, as a clinical-stage biotech, has a vested interest in understanding how FDA policies and timelines may impact its own drug development pipeline and investor expectations.

The details

During the webinar, Serina Therapeutics' CEO Steven Ledger will present on the company's strategic priorities for 2026 and discuss the future of the life sciences industry. Participants will have the opportunity to submit questions for the CEO, which will be relayed by Tribe Public's Managing Member, John F. Heerdink, Jr., who will host the event.

  • The webinar is scheduled for Wednesday, February 4, 2026 at 8:30 am pacific / 11:30 am eastern.

The players

Serina Therapeutics

A clinical-stage biotechnology company developing a pipeline of drug product candidates to treat neurological diseases and other indications using its proprietary POZ Platform™ technology.

Steven Ledger

The CEO of Serina Therapeutics.

Tribe Public LLC

A distinguished organization that facilitates corporate sponsored global webinars and in-person meetings events across the United States, with a focus on providing direct access to management teams and leading experts.

John F. Heerdink, Jr.

The Managing Member of Tribe Public LLC, who will host the webinar event.

Got photos? Submit your photos here. ›

What’s next

Participants can register for the complimentary webinar event at New-FDA-Era.TribePublic.com and submit questions for the CEO in advance to research@tribepublic.com or during the event via the ZOOM chat feature.

The takeaway

This webinar provides a valuable opportunity for life sciences companies and investors to gain insights into how evolving FDA policies and priorities in 2026 may impact drug development timelines, review processes, and investor expectations across the industry.